Gosset Ownership
Private
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Ibex Medical Analytics General Information
Ibex’s Galen™ platform has demonstrated near-perfect concordance with expert pathologists in clinical studies. The company’s flagship product “Ibex Prostate Detect” received FDA 510(k) clearance in February 2025 as an aid for detecting small and rare prostatic cancers. Clinical deployments have shown improved accuracy of diagnosis, comprehensive quality control measures, reduced turnaround times, and productivity gains up to 37% when integrated into digital pathology workflows.
Contact Information
Drug Pipeline
Galen Prostate
CommercialKey Partnerships
Philips (integration of AI tools into Philips IntelliSite Pathology Solution), Alverno Laboratories, Institut Curie
Ibex Medical Analytics Funding
No funding data available
To view Ibex Medical Analytics's complete valuation and funding history, request access »